MAKELL MURPHY: Open Payments
NPI 1255621694 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,816 in 96 payments from 16 companies in 2025. Trend: 2023 $2,043 · 2024 $2,177 · 2025 $1,816
Food & beverage: $1,816
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 27 | $498 |
| ABBVIE INC. | 16 | $227 |
| Medtronic, Inc. | 8 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $159 |
| Janssen Pharmaceuticals, Inc | 6 | $149 |
| Neurocrine BioSciences, Inc. | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 5 | $89 |
| Alkermes, Inc. | 4 | $73 |
| Amgen Inc. | 3 | $67 |
Products named: FANAPT, VRAYLAR, INTELLIS ADAPTIVESTIM, CAPLYTA, INVEGA SUSTENNA, INGREZZA, REXULTI, COBENFY.
Industry payments across CA — which companies pay providers there.
